Confronta i metodi
Esamina i metodi selezionati fianco a fianco; le righe che differiscono sono evidenziate.
| Scaling Farmacocinetico Allometrico× | Farmacocinetica Fisiologicamente Basata× | |
|---|---|---|
| Campo | Farmacologia | Farmacologia |
| Famiglia | Process / pipeline | Process / pipeline |
| Anno di origine≠ | 1989 | 1997 |
| Ideatore≠ | John Mordenti | Ivan Nestorov |
| Tipo≠ | inter-species extrapolation | predictive modeling |
| Fonte seminale≠ | Mordenti, J., & Chappell, W. (1989). The use of allometric scaling in toxicokinetic studies. Fundamental and Applied Toxicology, 13(2), 335-346. link ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Alias≠ | allometric scaling, inter-species extrapolation, FIH dose prediction | PBPK, PBPK modeling |
| Correlati | 3 | 3 |
| Sintesi≠ | Allometric scaling is a mathematical approach for predicting human pharmacokinetics from preclinical animal data using body weight relationships. Developed systematically by Mordenti and colleagues in the late 1980s, it enables rational first-in-human dose prediction without assuming species-specific metabolic differences. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateInsieme di dati ↗ |
|
|